The presymptomatic phase of type 1 diabetes is marked by the presence of two or more islet autoantibodies, classified into ...

In the USA, children with sickle cell disease increasingly survive into adulthood, leading to an expanding population of adults with significant comorbidities and complex medical needs that require ...

Advances in genetic cell modifications are performed routinely in research laboratories, but clinical translation requires ...

The past 10 years have seen an expansion in treatment possibilities for people with haemophilia, driven by the need for better protection against bleeding episodes, more efficient prevention of joint ...

In 2021, alcohol-related liver cirrhosis accounted for about a quarter of the 46·4 million disability-adjusted life-years (DALYs) lost from liver disease globally, making alcohol a leading cause of ...

In October, the UK NHS Blood and Transplant launched a campaign encouraging people to register as a stem cell donor, stating ...

Therein lies one of the most pragmatic reasons to address health inequity—inaction is financially unsustainable. However, ...

Now approved in over 20 cancer types and used in earlier lines of therapy, immune checkpoint inhibitors (ICIs) have ...

Despite substantial scientific advances, diagnosis and prognosis after paediatric traumatic brain injury (TBI) remains ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar ...

Margareth Dalcolmo has spent decades treating and researching respiratory infectious diseases, most notably tuberculosis. Yet ...

The SELECTION study1 showed that the JAK 1 inhibitor filgotinib is safe and efficacious in ulcerative colitis. Based on positive results of the phase 2 FITZROY study2 in Crohn's disease, it was ...